Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19.
J Mol Cell Cardiol
; 153: 72-85, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-989435
ABSTRACT
The first confirmed case of novel Coronavirus Disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of November 24, 2020, close to 12.2 million cases of COVID-19 was confirmed in the US, with over 255,958 deaths. The rapid transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), its unusual and divergent presentation has strengthened the status of COVID-19 as a major public health threat. In this review, we aim to 1- discuss the epidemiological data from various COVID-19 patient cohorts around the world and the USA as well the associated risk factors; 2- summarize the pathophysiology of SARS-CoV-2 infection and the underlying molecular mechanisms for the respiratory and cardiovascular manifestations; 3- highlight the potential treatments and vaccines as well as current clinical trials for COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
/
SARS-CoV-2
/
COVID-19
/
Lung Diseases
Type of study:
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
J Mol Cell Cardiol
Year:
2021
Document Type:
Article
Affiliation country:
J.yjmcc.2020.12.009
Similar
MEDLINE
...
LILACS
LIS